MedTrace Logo

Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea

NCT06295562 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-23

No results posted yet for this study

Summary

This study will conduct 3 intervention trials with 44 different participants in each trial, with 22 participants will undergo in-laboratory overnight polysomnograms (PSGs) at one night of medication intervention, and the other 22 at taking placebo (contained starch) 1 h before sleep. Three medication regimens will be tested: (1) atomoxetine 80mg combined with oxybutynin 5mg; (2) venlafaxine 37.5mg; and (3) oxybutynin 5mg combined with trazodone 100mg. Endotypic traits will be estimated using the Phenotyping Using Polysomnography method. The primary outcome is the change in apnea-hypopnea index, and secondary outcomes include endotypic traits and sleep parameters.

Conditions

  • Obstructive Sleep Apnea of Adult

Interventions

DRUG

Atomoxetine 80mg combined with oxybutynin 5mg

Atomoxetine 80mg combined with oxybutynin 5mg

DRUG

Venlafaxine 37.5mg

Venlafaxine 37.5mg

DRUG

oxybutynin 5mg combined with trazodone 100mg

oxybutynin 5mg combined with trazodone 100mg

DRUG

Placebo

Placebo tablet

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-05
Primary Completion
2025-10-10
Completion
2025-10-22

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06295562 on ClinicalTrials.gov